Curated News
By: NewsRamp Editorial Staff
March 10, 2026
hyperCORE International Welcomes Empathx Clinical Research to Expand Trial Access
TLDR
- hyperCORE International gains a strategic advantage by adding Empathx Clinical Research's eight-site network, expanding geographic reach and patient access for sponsors seeking efficient trial execution.
- Empathx Clinical Research joins hyperCORE's network through a hybrid model that integrates research sites within physician practices to streamline patient recruitment and trial management.
- This partnership expands patient access to clinical trials within their existing care environments, accelerating the development of life-changing therapies for communities nationwide.
- hyperCORE International now connects over 80 trial sites across five countries, having completed 7,000 studies with 140,000 participants through harmonized operational frameworks.
Impact - Why it Matters
This partnership matters because it directly addresses critical barriers in clinical research that affect both patients and medical progress. By integrating clinical trials into existing healthcare settings through Empathx's hybrid model, patients gain easier access to potentially life-saving treatments without disrupting their regular care routines—particularly important for those with chronic conditions like cardio-metabolic diseases or CNS disorders. For pharmaceutical companies and researchers, the expanded geographic reach and diverse patient populations across six states mean faster enrollment and more representative trial results, accelerating the development of new therapies. In an era where clinical trial delays and lack of diversity in participants have been persistent problems, this collaboration demonstrates how strategic alliances between research networks can create more efficient, patient-centered approaches to medical innovation.
Summary
In a significant expansion of clinical research capabilities, hyperCORE International has welcomed Empathx Clinical Research into its global partner site network, marking a strategic alliance that enhances patient access to clinical trials across the United States. The partnership, announced in March 2026, brings together hyperCORE International's extensive network of over 80 active trial sites across five countries with Empathx's eight clinical trial sites spanning six key states: California, Florida, Massachusetts, Michigan, Missouri, and Texas. This collaboration is particularly notable for its focus on advancing clinical trials in critical therapeutic areas including cardio-metabolic disease, central nervous system disorders, nephrology, and infectious disease, addressing some of the most pressing medical challenges of our time.
The integration is strengthened by Empathx's innovative hybrid model, which combines dedicated research centers with sites embedded within specialized physician practices, bringing clinical research directly into existing patient care environments. This approach, championed by CEO Dustin Owen—formerly Senior Vice President at Thermo Fisher Scientific/PPD—aligns perfectly with hyperCORE International's mission to expand patient access while maintaining high-quality trial execution. Owen emphasized that joining hyperCORE International represents a partnership with like-minded organizations committed to collaboration and quality, enhancing their ability to work with sponsors to bring life-changing therapies to communities through increased scale, geographic coverage, and access to diverse patient populations.
Nicholas Focil, President of hyperCORE International, highlighted how Empathx Clinical Research brings therapeutic expertise, geographic reach, and innovative site integration to their partner network, reinforcing hyperCORE's commitment to advancing clinical research through safe, ethical studies with strong enrollment and superior patient retention. Collectively, hyperCORE partners have completed over 7,000 studies involving more than 140,000 randomized participants, and this new partnership further strengthens their harmonized operational frameworks that support consistent, high-quality trial execution. The alliance represents a meaningful step forward in making clinical trials more accessible to patients while providing pharmaceutical sponsors with reliable solutions for delivering on their research objectives.
Source Statement
This curated news summary relied on content disributed by 24-7 Press Release. Read the original source here, hyperCORE International Welcomes Empathx Clinical Research to Expand Trial Access
